GlassScriptPhysician profile
Jonathan T Chao
NPI 1497249940
$4,737.01
in general payments reported to CMS, 2019-2025
18 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 82% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.87 · 2020: $199 · 2021: $642 · 2022: $925 · 2023: $482 · 2024: $700 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Travel and Lodging: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.88 |
| Travel and Lodging | $1,222.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,355.05 | 2025 | |
| Alcon Vision LLC | $1,037.90 | 2020-2024 | Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $576.22 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Glaukos Corporation | $393.47 | 2022-2024 | Ce-Marked Kxla System |
| Johnson & Johnson Surgical Vision, INC. | $257.70 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $180.65 | 2023-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $129.85 | 2021 | |
| Genentech USA, INC. | $127.17 | 2022 | |
| Horizon Therapeutics Plc | $122.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.92 | 2021 | |
| Ani Pharmaceuticals, INC. | $114.96 | 2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.18 | 2020-2021 | |
| Dompe US, INC. | $57.77 | 2025 | Oxervate |
| Abbvie INC. | $49.74 | 2024 | |
| Oyster Point Pharma, INC. | $42.44 | 2023-2024 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.44 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $18.32 | 2025 | Xdemvy |
| Beaver-Visitec International, INC. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.